Drug Approval | August 11, 2025
Shilpa Medicare receives approval of NorUDCA tablets for treatment of NAFLD in India
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Cupid reported total income of Rs. 64.75 crore in Q1 FY26 as compared to Rs. 44.03 crore in Q1 Fy25
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
With this addition, the company’s total Installed MCC Capacity will rise to 30,000 MTPA
The Q-Switched Nd:YAG system is suitable for all skin types and offers versatility in treating dermal and epidermal pigmentation
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
Subscribe To Our Newsletter & Stay Updated
